ESPL1

ESPL1/Separase is the protease responsible for cleaving chromosomal cohesin to enable sister chromatid separation, and it functions as a central guardian of genome segregation fidelity (PMID:40794720). Genetic loss-of-function in two vertebrate models (loach and zebrafish) demonstrates that ESPL1 is essential for mitotic sister chromatid separation in spermatogonia, with heterozygous knockout causing chromosome number doubling and unreduced diploid sperm (PMID:40794720), while its activity in meiosis is gated by a p53/CDK1 axis whose dysregulation under iron overload drives premature cohesin cleavage, spindle abnormalities, and aneuploidy in aged oocytes (PMID:42214643). Conversely, ESPL1 overexpression in mammary epithelium produces chromosomal instability—premature chromatid separation, anaphage bridges, micronuclei, and centrosome amplification—linking dosage imbalance to tumorigenesis (PMID:24276237). Beyond cohesin cleavage, ESPL1 physically associates with nuclear lamins at the nuclear envelope and is required for normal nuclear morphology, and its depletion in human fibroblasts elevates lamin A and distorts nuclei [PMID:bio_10.1101_2025.02.19.638993]. ESPL1 expression is tightly controlled: it is transcriptionally activated by c-MYB (PMID:26937281) and PAX2 (PMID:38573552), and its mRNA stability is governed by an m6A circuit in which BRD4-directed degradation of the demethylase ALKBH5 preserves IGF2BP3-dependent ESPL1 transcript stability (PMID:40370540). In cancer, elevated ESPL1 engages the JAK2/STAT3 pathway to confer cisplatin resistance (PMID:38573552) and interacts with the E3 ligase MDM2 in the context of apatinib resistance (PMID:38402402).

1. 2013 Medium

   Establishing that ESPL1 dosage matters in vivo, overexpression was shown to actively destabilize chromosome segregation rather than being merely a passive cleavage enzyme.

   Evidence MMTV-Espl1 transgenic mouse model with cytogenetic analysis of mammary tumors

   PMID:24276237

   Open questions at the time

   • Does not establish whether the instability arises from excess cohesin cleavage or from off-target substrates
   • Does not define ESPL1 protease activity directly in the tumor cells
2. 2016 Medium

   Addressed how ESPL1 levels are set, identifying c-MYB as a direct transcriptional driver of Separase expression.

   Evidence Gelshift, ChIP, c-MYB silencing with qRT-PCR/Western in CML cell lines

   PMID:26937281

   Open questions at the time

   • Does not connect c-MYB-driven ESPL1 levels to a segregation or disease phenotype
   • Single cell-type context (CML)
3. 2024 Medium

   Extended the transcriptional control logic and linked ESPL1 output to a drug-resistance signaling axis, showing PAX2 activates ESPL1 which feeds the JAK2/STAT3 pathway.

   Evidence ChIP, luciferase reporter, siRNA, AG490 inhibition, xenograft in bladder cancer cells

   PMID:38573552

   Open questions at the time

   • Mechanism by which a cohesin protease engages JAK2/STAT3 is not defined
   • Whether the effect requires ESPL1 protease activity is untested
4. 2024 Low

   Identified a physical partner outside the segregation machinery, placing ESPL1 in contact with the E3 ligase MDM2 in a drug-resistance setting.

   Evidence Co-immunoprecipitation plus CRISPR gain-of-function screen in gastric cancer cells

   PMID:38402402

   Open questions at the time

   • Single Co-IP without reciprocal validation or mapping of the interaction
   • No functional consequence of the ESPL1-MDM2 interaction established
   • Directionality (is ESPL1 an MDM2 substrate?) unknown
5. 2025 Medium

   Defined post-transcriptional control of ESPL1, showing its mRNA stability depends on an m6A reader/eraser balance set by BRD4-mediated ALKBH5 turnover.

   Evidence siRNA, JQ1, co-IP of BRD4/TRIM21/ALKBH5, m6A quantification, IGF2BP3 RIP, animal and clinical validation

   PMID:40370540

   Open questions at the time

   • Awaits independent replication
   • Does not map the specific m6A sites on ESPL1 mRNA functionally
   • Connection to ESPL1's segregation function not tested
6. 2025 High

   Provided the cleanest genetic proof of ESPL1's core function, demonstrating it is essential for mitotic sister chromatid separation in a whole animal.

   Evidence CRISPR/Cas9 heterozygous knockout in loach and zebrafish with ploidy and spermatogonial cytology

   PMID:40794720

   Open questions at the time

   • Does not directly visualize cohesin cleavage by ESPL1 in this system
   • Haploinsufficiency mechanism for the dominant unreduced-sperm phenotype not fully resolved
7. 2025 Medium

   Uncovered a non-canonical role at the nuclear envelope, showing ESPL1 physically and functionally associates with lamins to maintain nuclear architecture.

   Evidence Reciprocal co-IP in Drosophila and human fibroblasts, IF colocalization, ESPL1 siRNA with nuclear morphology and locomotion assays (preprint)

   PMID:bio_10.1101_2025.02.19.638993

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Whether lamins are proteolytic substrates of ESPL1 is not established
   • Independence from the cohesin-cleavage function unclear
8. 2026 Medium

   Connected upstream stress signaling to ESPL1 activity in meiosis, showing a p53/CDK1 axis gates Separase to prevent premature cohesin cleavage in oocytes.

   Evidence Naturally aged and FeSO4 iron-overload mouse models, adenoviral manipulation, oocyte culture, spindle/chromosome analysis

   PMID:42214643

   Open questions at the time

   • Whether CDK1 regulates ESPL1 directly versus indirectly is not resolved
   • Single lab; generality beyond iron-overload aging context untested

• How ESPL1's regulatory inputs (c-MYB, PAX2, m6A, p53/CDK1) and non-canonical lamin interaction integrate to control its protease activity in time and space remains unresolved.
• No structural or biochemical reconstitution in the corpus linking regulators to protease state
• Whether lamins and MDM2 are substrates versus binding partners is undetermined
• No unified model coupling transcriptional, post-transcriptional, and signaling control